Redefining use of MRI for patients with multiple sclerosis
- PMID: 34302777
- DOI: 10.1016/S1474-4422(21)00203-9
Redefining use of MRI for patients with multiple sclerosis
Conflict of interest statement
JK received research funds from Dainippon Sumitomo Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, and Kyowa Kensetsukougyo, and consultancy fees, speaking fees, or honoraria from Novartis Pharma, Mitsubishi Tanabe Pharma, CSL Behring, Biogen Japan, Teijin Health Care, the Takeda Pharmaceutical Company, Kyowa Kirin, Ono Pharmaceutical, Alexion Pharmaceuticals, Tsumura, Ricoh, EMC, and Eisai.
Comment on
-
2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.Lancet Neurol. 2021 Aug;20(8):653-670. doi: 10.1016/S1474-4422(21)00095-8. Epub 2021 Jun 14. Lancet Neurol. 2021. PMID: 34139157 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical